These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 32527933

  • 1. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
    Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, Roca Ho H, Castella M, Zanetti SR, Velasco Hernandez T, Diaz de la Guardia R, Castaño J, Anguita E, Vives S, Nomdedeu J, Lapillone H, Bras AE, van der Velden VHJ, Junca J, Marin P, Bataller A, Esteve J, Vick B, Jeremias I, Lopez A, Sorigue M, Bueno C, Menendez P.
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32527933
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A, Bonnet D, Biagi E.
    Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
    [Abstract] [Full Text] [Related]

  • 6. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T, McNamara G, Cooper LJ.
    PLoS One; 2016 May; 11(8):e0159477. PubMed ID: 27548616
    [Abstract] [Full Text] [Related]

  • 7. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Zhou L, Liu X, Wang X, Sun Z, Song XT.
    Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
    [Abstract] [Full Text] [Related]

  • 8. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
    Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, Biondi A, Biagi E, Bonnet D.
    Leukemia; 2014 Aug; 28(8):1596-605. PubMed ID: 24504024
    [Abstract] [Full Text] [Related]

  • 9. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA, Kloos A, Lenz D, Kattre N, Nowak J, Bentele M, Keisker M, Dahlke J, Zimmermann K, Sauer M, Heuser M, Schambach A.
    Viruses; 2021 Jul 14; 13(7):. PubMed ID: 34372571
    [Abstract] [Full Text] [Related]

  • 10. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H, Yang L, Chukinas JA, Shah N, Tarun S, Pouzolles M, Chien CD, Niswander LM, Welch AR, Taylor N, Tasian SK, Fry TJ.
    J Immunother Cancer; 2021 Sep 14; 9(9):. PubMed ID: 34531250
    [Abstract] [Full Text] [Related]

  • 11. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.
    Blood; 2017 Apr 27; 129(17):2395-2407. PubMed ID: 28246194
    [Abstract] [Full Text] [Related]

  • 12. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
    Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, Biagi E, Tettamanti S, Varani L.
    Mol Ther; 2017 Aug 02; 25(8):1933-1945. PubMed ID: 28479045
    [Abstract] [Full Text] [Related]

  • 13. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
    Atilla PA, McKenna MK, Watanabe N, Mamonkin M, Brenner MK, Atilla E.
    Cytotherapy; 2022 Mar 02; 24(3):282-290. PubMed ID: 34955406
    [Abstract] [Full Text] [Related]

  • 14. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.
    El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C, Lopez AF, Brown MP, Duyster J, Hein L, Manz MG, Hughes TP, White DL, Yong ASM, Zeiser R.
    Nat Commun; 2021 Nov 08; 12(1):6436. PubMed ID: 34750374
    [Abstract] [Full Text] [Related]

  • 15. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D, Li Z, Zhang X, Yang Y, Yuan X, Zhang X, Yang M, Zhang Y, Xiong D.
    J Hematol Oncol; 2015 Feb 28; 8():18. PubMed ID: 25879549
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
    Meyer JE, Loff S, Dietrich J, Spehr J, Jurado Jiménez G, von Bonin M, Ehninger G, Cartellieri M, Ehninger A.
    Oncoimmunology; 2021 Feb 28; 10(1):1945804. PubMed ID: 34290907
    [Abstract] [Full Text] [Related]

  • 17. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.
    Bôle-Richard E, Fredon M, Biichlé S, Anna F, Certoux JM, Renosi F, Tsé F, Molimard C, Valmary-Degano S, Jenvrin A, Warda W, Pallandre JR, Bonnefoy F, Poussard M, Deschamps M, Petrella T, Roumier C, Macintyre E, Féger F, Brissot E, Mohty M, HoWangYin KY, Langlade-Demoyen P, Loustau M, Caumartin J, Godet Y, Binda D, Pagadoy M, Deconinck E, Daguindau E, Saas P, Ferrand C, Angelot-Delettre F, Adotévi O, Garnache-Ottou F.
    Leukemia; 2020 Dec 28; 34(12):3228-3241. PubMed ID: 32111969
    [Abstract] [Full Text] [Related]

  • 18. Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.
    Zeng Z, Roobrouck A, Deschamps G, Bonnevaux H, Guerif S, De Brabandere V, Amara C, Dejonckheere E, Virone-Oddos A, Chiron M, Konopleva M, Dullaers M.
    Blood Adv; 2024 May 14; 8(9):2059-2073. PubMed ID: 38266153
    [Abstract] [Full Text] [Related]

  • 19. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
    Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.
    Blood; 2014 Apr 10; 123(15):2343-54. PubMed ID: 24596416
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.